Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States

Journal of Clinical Microbiology

Volumn 48, Issue 2, 2010, Pages 539-544

  Iqbal, Naureen ^a   DeBess, Emilio E ^b   Wohrle, Ron ^c   Sun, Ben ^d   Nett, Randall J ^a,e   Ahlquist, Angela M ^a   Chiller, Tom ^a   Lockhart, Shawn R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b OREGON DEPARTMENT OF HUMAN SERVICES   (United States)

^c WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

^d CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^e Idaho Department of Health and Welfare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCUS; CRYPTOCOCCUS GATTII; FUNGAL STRAIN; FUNGUS ISOLATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PRIORITY JOURNAL; UNITED STATES;

ANIMALS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DNA FINGERPRINTING; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MYCOLOGICAL TYPING TECHNIQUES; NORTHWESTERN UNITED STATES; SEQUENCE ANALYSIS, DNA;

CRYPTOCOCCUS GATTII;

EID: 75649148761     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01505-09     Document Type: Article

References (31)

1. Aller, A. I., E. Martin-Mazuelos, F. Lozano, J. Gomez-Mateos, L. Steele-Moore, W. J. Holloway, M. J. Gutiérrez, F. J. Recio, and A. Espinel-Ingroff. 2000. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob. Agents Chemother. 44:1544-1548.
2. Bovers, M., F. Hagen, and T. Boekhout. 2008. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev. Iberoam. Micol. 25:S4-S12.
3. Brandt, M. E., L. C. Hutwagner, L. A. Klug, W. S. Baughman, D. Rimland, E. A. Graviss, R. J. Hamill, C. Thomas, P. G. Pappas, A. L. Reingold, and R. W. Pinner. 1996. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J. Clin. Microbiol. 34:912-917.
4. Byrnes, E. J., III, R. J. Bildfell, S. A. Frank, T. G. Mitchell, K. A. Marr, and J. Heitman. 2009. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J. Infect. Dis. 199:1081-1086.
5. Chen, S., T. Sorrell, G. Nimmo, B. Speed, B. Currie, D. Ellis, D. Marriott, T. Pfeiffer, D. Parr, and K. Byth. 2000. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin. Infect. Dis. 31:499-508.
6. Chen, Y. C., S. C. Chang, C. C. Shih, C. C. Hung, K. T. Luhbd, Y. S. Pan, and W. C. Hsieh. 2000. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn. Microbiol. Infect. Dis. 36:175-183.
7. Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, third edition. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Dannaoui, E., M. Abdul, M. Arpin, A. Michel-Nguyen, M. A. Piens, A. Favel, O. Lortholary, F. Dromer, and the French Cryptococcosis Study Group. 2006. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob. Agents Chemother. 50:2464-2470.
9. De Bedout, C., N. Ordóñez, B. L. Gómez, M. C. Rodríguez, M. Arango, A. Restrepo, and E. Castañeda. 1999. In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii. Rev. Iberoam. Micol. 16:36-39.
10. Duncan, C., H. Schwantje, C. Stephen, J. Campbell, and K. Bartlett. 2006. Cryptococcus gattii in wildlife of Vancouver Island, British Columbia, Canada. J. Wildl. Dis. 42:175-178.
11. Ellis, D., and T. Pfeiffer. 1992. The ecology of Cryptococcus neoformans. Eur. J. Epidemiol. 8:321-325.
12. Fraser, J. A., S. S. Giles, E. C. Wenink, S. G. Geunes-Boyer, J. R. Wright, S. Diezmann, A. Allen, J. E. Stajich, F. S. Dietrich, J. R. Perfect, and J. Heitman. 2005. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437:1360-1364.
13. Galanis, E. L. MacDougall, M. Li, J. Woolcott, R. Mitchell, and Y. Peng. 2008. Burden of illness and risk factors for C. gattii infection in British Columbia (BC), Canada, 1999-2007, poster A-24. Abstr. 7th Intl. Conf. Cryptococcus and Cryptococcosis, 2008, Nagasaki, Japan.
14. Hoang, L. M., J. A. Maguire, P. Doyle, M. Fyfe, and D. L. Roscoe. 2004. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J. Med. Microbiol. 53:935-940.
15. Jain, N., B. L. Wickes, S. M. Keller, J. Fu, A. Casadevall, P. Jain, M. A. Ragan, U. Banerjee, and B. C. Fries. 2005. Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J. Clin. Microbiol. 43: 5733-5742.
16. Kidd, S. E., Y. Chow, S. Mak, P. J. Bach, H. Chen, A. O. Hingston, J. W. Kronstad, and K. H. Bartlett. 2007. Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States. Appl. Environ. Microbiol. 73:1433-1443.
17. Kidd, S. E., H. Guo, K. H. Bartlett, J. Xu, and J. W. Kronstad. 2005. Comparative gene genealogies indicate that two clonal lineages of Cryptococcus gattii in British Columbia resemble strains from other geographical areas. Eukaryot. Cell 4:1629-1638.
18. Kidd, S. E., F. Hagen, R. L. Tscharke, M. Huynh, K. H. Bartlett, M. Fyfe, L. Macdougall, T. Boekhout, K. J. Kwon-Chung, and W. Meyer. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. U. S. A. 101:17258-17263.
19. Kwon-Chung, K. J., and J. E. Bennett. 1984. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am. J. Epidemiol. 120:123-130.
20. Kwon-Chung, K. J., I. Polacheck, and J. E. Bennett. 1982. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J. Clin. Microbiol. 15:535-537.
21. MacDougall, L., S. E. Kidd, E. Galanis, S. Mak, M. J. Leslie, P. R. Cieslak, J. W. Kronstad, M. G. Morshed, and K. H. Bartlett. 2007. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg. Infect. Dis. 13:42-50.
22. Meyer, W., D. M. Aanensen, T. Boekhout, M. Cogliati, M. R. Diaz, M. C. Esposto, M. Fisher, F. Gilgado, F. Hagen, S. Kaocharoen, A. P. Litvintseva, T. G. Mitchell, S. P. Simwami, L. Trilles, M. A. Viviani, and J. Kwon-Chung. 2009. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med. Mycol. 12:1-14.
23. Miller, W. G., A. A. Padhye, W. van Bonn, E. Jensen, M. E. Brandt, and S. H. Ridgway. 2002. Cryptococcosis in a bottlenose dolphin (Tursiops truncatus) caused by Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 40:721-724.
24. Morera-López, Y., J. M. Torres-Rodríguez, T. Jiménez-Cabello, and T. Baró-Tomás. 2005. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med. Mycol. 43:505-510.
25. Morgan, J., K. M. McCarthy, S. Gould, K. Fan, B. Arthington-Skaggs, N. Iqbal, K. Stamey, R. A. Hajjeh, M. E. Brandt, and the Gauteng Cryptococcal Surveillance Initiative Group. 2006. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin. Infect. Dis. 43:1077-1080.
26. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, G. V. Doern, and D. J. Diekema. 2005. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43:2163-2167.
27. Thompson, G. R., III, N. P. Wiederhold, A. W. Fothergill, A. C. Vallor, B. L. Wickes, and T. F. Patterson. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53:309-311.
28. Trilles, L., B. Fernández-Torres, S. Lazéra Mdos, B. Wanke, and J. Guarro. 2004. In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42:4815-4817.
29. Upton, A., J. A. Fraser, S. E. Kidd, C. Bretz, K. H. Bartlett, J. Heitman, and K. A. Marr. 2007. First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak. J. Clin. Microbiol. 45:3086-3088.
30. Viviani, M. A., M. Cogliati, M. C. Esposto, K. Lemmer, K. Tintelnot, M. F. Colom Valiente, D. Swinne, A. Velegraki, R. Velho, and the European Confederation of Medical Mycology (ECMM) Cryptococcosis Working Group. 2006. Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM survey of cryptococcosis in Europe. FEMS Yeast Res. 6:614-619.
31. West, S. K., E. Byrnes, S. Mostad, R. Thompson, R. Barnes, C. Beiser, J. Heitman, and K. A. Marr. 2005. Emergence of Cryptococcus gattii in the Pacific Northwest United States, abstract M-1849. Abstr. 46th Annu. Meet. Infect. Dis. Soc. Amer., Infectious Diseases Society of America, Washington, DC.